
The retinoic acid metabolism-blocking agent (RAMBA) Rambazole (Barrier Therapeutics) has demonstrated promising efficacy and safety as a novel oral treatment for acne in early clinical trials along with potential activity as a topically applied agent. Based on those results, this novel compound is about to proceed into further testing of its topical use in a multicenter, randomized, double-blind, vehicle-controlled study and for oral administration in a double–blind, dose-finding study.


